The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
V | Various | |
2
|
V10 | Therapeutic radiopharmaceuticals | |
3
|
V10X | Other therapeutic radiopharmaceuticals | |
4
|
V10XX | Various therapeutic radiopharmaceuticals | |
5
|
V10XX04 |
| Active Ingredient |
|---|
|
Lutetium (177Lu) oxodotreotide has a high affinity for subtype 2 somatostatin receptors (sst2). It binds to malignant cells which overexpress sst2 receptors. Lutetium-177 (177Lu) is a βemitting radionuclide with a maximum penetration range in tissue of 2.2 mm (mean penetration range of 0.67 mm), which is sufficient to kill targeted tumour cells with a limited effect on neighbouring normal cells. |
| Document | Type | Information Source | |
|---|---|---|---|
| LUTATHERA Solution for infusion | MPI, EU: SmPC | European Medicines Agency (EU) | |
| LUTATHERA Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.